CAR-T therapies: Faster, better, cheaper
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Working in the in vivo cell therapy space, Johnson discusses the injection of a manufactured vector into a patient to create the CAR-T cells directly inside the body of the patient, without the need for chemotherapy treatment beforehand – hence such hope for in vivo cell therapy’s potential. Targeting both T-cells and NK-cells, Johnson notes that this is a distinguishing factor of the work Interius does.
On the CAR-T space generally, Comstock and Johnson explore its evolution and how these products can be made faster, better, and cheaper – including the democratisation of these therapies, and the accessibility gains this means for patients.
You can listen to episode 132 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
